The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Pacira BioSciences, Inc.
LOS ANGELES, CA / ACCESS Newswire / February 1, 2025
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ:PCRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before March 14, 2025.
The lawsuit alleges that Pacira made false and misleading statements about the safety and efficacy of its products, causing harm to investors. The class action seeks to recover damages for investors who suffered losses during the Class Period.
If you are a shareholder who purchased Pacira securities during the Class Period, it is important to reach out to the Schall Law Firm to protect your rights and explore your legal options.
For more information on the class action lawsuit against Pacira BioSciences, Inc., and to contact the Schall Law Firm, visit their website.
How will this affect me?
As an investor who purchased Pacira securities between August 2, 2023, and August 8, 2024, you may be eligible to join the class action lawsuit against the Company. By contacting the Schall Law Firm before March 14, 2025, you can protect your rights and potentially recover damages for any losses you incurred during the Class Period.
How will this affect the world?
The outcome of the class action lawsuit against Pacira BioSciences, Inc. could have broader implications for the pharmaceutical industry and investors as a whole. If the allegations of false and misleading statements are proven true, it may lead to increased scrutiny and regulation of companies’ claims about the safety and efficacy of their products, ultimately benefiting investors by promoting transparency and accountability in the market.
Conclusion
Investors who purchased Pacira securities during the Class Period should take action to protect their rights and potentially recover damages by contacting the Schall Law Firm before March 14, 2025. The outcome of the class action lawsuit against Pacira BioSciences, Inc. may have far-reaching effects on the pharmaceutical industry and investor protection, highlighting the importance of holding companies accountable for their statements and actions.
